2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference
01 Agosto 2023 - 3:15PM
Business Wire
2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology
cell therapy company, announced today that members of the
management team will present at the upcoming 2023 Wedbush PacGrow
Healthcare Conference on August 8, 2023 at 8:00am ET in New
York.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME.
Cancer rips time away, and our goal is to work at the maximum speed
of translating human thought into action – 270 miles per hour – to
give the people we serve more time. We are building the leading
immuno-oncology cell therapy company, focused on discovering and
developing new therapies that truly disrupt the cancer treatment
landscape.
With a deep understanding of the human body’s immune response to
tumor cells and how to translate cell therapies into practice,
we’re applying this knowledge to deliver next generation cellular
therapies that focus on a broad range of hematologic malignancies,
including the first FDA-approved CAR T cell therapy for multiple
myeloma, as well as solid tumors. Our research and development is
focused on delivering therapies that are designed with the goal to
“think” smarter and faster than the disease. Importantly, we remain
focused on accomplishing these goals by staying genuine and
authentic to our “why” and keeping our people and culture top of
mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and
LinkedIn.
2seventy bio is a trademark of 2seventy bio, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230801285816/en/
Media & Investors: Jenn Snyder 617-448-0281
jenn.snyder@2seventybio.com
Morgan Adams 774-313-9852 morgan.adams@2seventybio.com
2seventy bio (NASDAQ:TSVT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
2seventy bio (NASDAQ:TSVT)
Gráfica de Acción Histórica
De May 2023 a May 2024